KR20230005239A - 경구 투여용 신규한 지연 방출 조성물 - Google Patents

경구 투여용 신규한 지연 방출 조성물 Download PDF

Info

Publication number
KR20230005239A
KR20230005239A KR1020227040358A KR20227040358A KR20230005239A KR 20230005239 A KR20230005239 A KR 20230005239A KR 1020227040358 A KR1020227040358 A KR 1020227040358A KR 20227040358 A KR20227040358 A KR 20227040358A KR 20230005239 A KR20230005239 A KR 20230005239A
Authority
KR
South Korea
Prior art keywords
dosage form
treatment
acid
capsule
salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020227040358A
Other languages
English (en)
Korean (ko)
Inventor
올라 캠버
크리스티나 요한슨
Original Assignee
바이코어 파마 아베
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 바이코어 파마 아베 filed Critical 바이코어 파마 아베
Publication of KR20230005239A publication Critical patent/KR20230005239A/ko
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A61K9/4825—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4891—Coated capsules; Multilayered drug free capsule shells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020227040358A 2020-04-24 2021-04-23 경구 투여용 신규한 지연 방출 조성물 Pending KR20230005239A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB2006074.5 2020-04-24
GBGB2006074.5A GB202006074D0 (en) 2020-04-24 2020-04-24 New composition
PCT/GB2021/050993 WO2021214487A1 (en) 2020-04-24 2021-04-23 New delayed release composition for peroral administration

Publications (1)

Publication Number Publication Date
KR20230005239A true KR20230005239A (ko) 2023-01-09

Family

ID=71080159

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020227040358A Pending KR20230005239A (ko) 2020-04-24 2021-04-23 경구 투여용 신규한 지연 방출 조성물

Country Status (26)

Country Link
US (4) US11654115B2 (cg-RX-API-DMAC7.html)
EP (2) EP4218737A1 (cg-RX-API-DMAC7.html)
JP (3) JP7418587B2 (cg-RX-API-DMAC7.html)
KR (1) KR20230005239A (cg-RX-API-DMAC7.html)
CN (1) CN115811971A (cg-RX-API-DMAC7.html)
AU (2) AU2021258542B2 (cg-RX-API-DMAC7.html)
BR (1) BR112022021520A2 (cg-RX-API-DMAC7.html)
CA (1) CA3180850A1 (cg-RX-API-DMAC7.html)
DK (1) DK4138789T3 (cg-RX-API-DMAC7.html)
ES (1) ES2955915T3 (cg-RX-API-DMAC7.html)
FI (1) FI4138789T3 (cg-RX-API-DMAC7.html)
GB (1) GB202006074D0 (cg-RX-API-DMAC7.html)
HR (1) HRP20231012T1 (cg-RX-API-DMAC7.html)
HU (1) HUE062897T2 (cg-RX-API-DMAC7.html)
IL (1) IL297374B2 (cg-RX-API-DMAC7.html)
LT (1) LT4138789T (cg-RX-API-DMAC7.html)
MA (1) MA59397B1 (cg-RX-API-DMAC7.html)
MD (1) MD4138789T2 (cg-RX-API-DMAC7.html)
MX (1) MX2022013069A (cg-RX-API-DMAC7.html)
PL (1) PL4138789T3 (cg-RX-API-DMAC7.html)
PT (1) PT4138789T (cg-RX-API-DMAC7.html)
RS (1) RS64568B1 (cg-RX-API-DMAC7.html)
SI (1) SI4138789T1 (cg-RX-API-DMAC7.html)
SM (1) SMT202300289T1 (cg-RX-API-DMAC7.html)
WO (1) WO2021214487A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202211461B (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB202004094D0 (en) * 2020-03-20 2020-05-06 Vicore Pharma Ab New compounds and uses
GB202006074D0 (en) 2020-04-24 2020-06-10 Vicore Pharma Ab New composition
GB202006079D0 (en) 2020-04-24 2020-06-10 Vicore Pharma Ab New composition
KR20240148359A (ko) 2022-02-10 2024-10-11 바이코어 파마 아베 특발성 폐섬유증 치료를 위한 불록시부티드의 용도
GB202201723D0 (en) * 2022-02-10 2022-03-30 Vicore Pharma Ab New use

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS59139317A (ja) * 1983-01-31 1984-08-10 Teisan Seiyaku Kk 持続性のニフエジピン製剤
SE9800550D0 (sv) 1998-02-24 1998-02-24 A & Science Invest Ab A pharmaceutical preparation comprising an angiotensin II type 2 receptor agonist, and use thereof
DE60222409T2 (de) 2001-05-31 2008-09-25 Vicore Pharma Ab Trizyklische verbindungen, nützlich als angiotensin ii agonisten
JP2003325642A (ja) * 2002-05-09 2003-11-18 Sansho Pharmaceutical Co Ltd 腸溶性皮膜付き硬質空カプセルと、腸溶性皮膜付き硬質空カプセルの製造方法と、腸溶性皮膜付き硬質カプセル剤
MXPA06004029A (es) * 2003-10-10 2006-06-28 Solvay Pharm Gmbh Composicion farmaceutica que comprende un agonista del receptor de imidazolina selectivo i1 y un bloqueante del receptor de angiotensina ii.
WO2005123072A1 (en) * 2004-06-14 2005-12-29 Sepracor Inc. Methods and compositions for the treatment of pulmonary diseases
PE20060777A1 (es) 2004-12-24 2006-10-06 Boehringer Ingelheim Int Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas
EP2946774B1 (en) 2014-05-19 2020-04-22 Tillotts Pharma AG Modified release coated capsules
EP2946773A1 (en) * 2014-05-19 2015-11-25 Tillotts Pharma AG Modified release coated capsules
HK1244232A1 (zh) * 2015-03-02 2018-08-03 维科尔药物公司 用於治疗肺纤维化的血管紧张素ii受体激动剂
JPWO2017022248A1 (ja) * 2015-08-04 2018-05-24 富士カプセル株式会社 腸溶性カプセル
WO2017221012A1 (en) 2016-06-21 2017-12-28 Vicore Pharma Ab Methods and compositions for preventing or reducing the risk of cancer treatment-related cardiotoxicity
GB201710906D0 (en) 2017-07-06 2017-08-23 Vicore Pharma Ab Compounds and methods for treating peripheral neuropathy
US11931341B2 (en) * 2018-03-22 2024-03-19 University Of Lowa Research Foundation Compositions and methods for the treatment and prevention of muscular dystrophy
JP7044360B2 (ja) * 2018-04-02 2022-03-30 三生医薬株式会社 ハードカプセル用コーティング剤及びそれを用いたハードカプセル剤の製造方法
GB201818164D0 (en) 2018-11-07 2018-12-19 Vicore Pharma Ab New composition
GB202006074D0 (en) * 2020-04-24 2020-06-10 Vicore Pharma Ab New composition
GB202006079D0 (en) 2020-04-24 2020-06-10 Vicore Pharma Ab New composition
GB202201723D0 (en) 2022-02-10 2022-03-30 Vicore Pharma Ab New use

Also Published As

Publication number Publication date
ZA202211461B (en) 2025-02-26
EP4218737A1 (en) 2023-08-02
JP7663647B2 (ja) 2025-04-16
JP2023504292A (ja) 2023-02-02
JP7862634B2 (ja) 2026-05-19
WO2021214487A1 (en) 2021-10-28
EP4138789A1 (en) 2023-03-01
GB202006074D0 (en) 2020-06-10
EP4138789B1 (en) 2023-06-07
LT4138789T (lt) 2023-09-25
ES2955915T3 (es) 2023-12-11
US20220202729A1 (en) 2022-06-30
RS64568B1 (sr) 2023-10-31
IL297374B2 (en) 2026-05-01
HRP20231012T1 (hr) 2023-12-08
JP2025106410A (ja) 2025-07-15
HUE062897T2 (hu) 2023-12-28
SMT202300289T1 (it) 2023-11-13
AU2021258542B2 (en) 2026-03-12
PT4138789T (pt) 2023-08-29
AU2026203703A1 (en) 2026-05-28
US20230364022A1 (en) 2023-11-16
MA59397B1 (fr) 2023-11-30
SI4138789T1 (sl) 2023-11-30
US12121614B2 (en) 2024-10-22
MX2022013069A (es) 2022-11-30
AU2021258542A1 (en) 2022-12-01
CA3180850A1 (en) 2021-10-28
IL297374A (en) 2022-12-01
US11654115B2 (en) 2023-05-23
US20260007608A1 (en) 2026-01-08
IL297374B1 (en) 2026-01-01
PL4138789T3 (pl) 2023-12-11
DK4138789T3 (da) 2023-09-11
FI4138789T3 (fi) 2023-08-28
JP2024001089A (ja) 2024-01-09
JP7418587B2 (ja) 2024-01-19
BR112022021520A2 (pt) 2023-01-24
US20250235408A1 (en) 2025-07-24
MD4138789T2 (ro) 2023-11-30
CN115811971A (zh) 2023-03-17

Similar Documents

Publication Publication Date Title
JP7663647B2 (ja) 経口投与用の新しい遅延放出組成物
JP7387903B2 (ja) 経口投与用の新しい乾燥粉末組成物
US11819494B2 (en) Treatment of idiopathic pulmonary fibrosis
US20250177355A1 (en) Treatment of idiopathic pulmonary fibrosis
US20230149362A1 (en) New capsule composition for peroral administration
HK40090175A (en) New delayed release composition for peroral administration
HK40088609A (en) New delayed release composition for peroral administration
HK40088609B (en) New delayed release composition for peroral administration
EA049971B1 (ru) Новая композиция с отсроченным высвобождением для перорального введения

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PE0801 Dismissal of amendment

St.27 status event code: A-2-2-P10-P12-nap-PE0801

D21 Rejection of application intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902